Sona Nanotech’s THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the ‘Company’, ‘Sona’) announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy (‘THT’) which uses the Company’s patented, biocompatible…